A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Sponsor:

Corvus Pharmaceuticals, Inc.

Sponsor Study ID:

CPI-818-004

CTO #:

104302

NCT Number:

NCT06561048

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

Progression-free survival (PFS) of soquelitinib compared to standard of care (SOC) per Independent Review Committee (IRC) assessment.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)